Zobrazeno 1 - 10
of 53
pro vyhledávání: '"B. Egerdie"'
Autor:
Karl R. Westenfelder, Scott Montgomery, Yair Lotan, Donna Mayne, Joseph Zadra, Godfrey K. Jansz, Scott Campbell, Eric W. Klein, Safedin Beqaj, Richard Harris, Ellen Wallace, Timothy A. Richardson, Bernard Goldfarb, Michael B. Williams, Alon Z. Weizer, Julia A. Bridge, Andrew M. Hiar, Kevin Cline, Xixi Lu, John Danella, Russell B. Egerdie, Timothy J. Bradford, Iris M. Simon, Franciscus Johannes P. van Valenberg, Andrew F. Trainer, J. Alfred Witjes, Fred Wolk, Michael Bates, Wade J. Sexton, Arnulf Stenzl, Russell Higuchi, Richard D. David
Publikováno v:
European Urology Oncology, 4, 1, pp. 93-101
European Urology Oncology, 4, 93-101
European Urology Oncology, 4, 93-101
Contains fulltext : 245130.pdf (Publisher’s version ) (Open Access) BACKGROUND: In patients with haematuria, a fast, noninvasive test with high sensitivity (SN) and negative predictive value (NPV), which is able to detect or exclude bladder cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::901715197fe47d19ae21bff2290f55e8
https://doi.org/10.1016/j.euo.2020.09.001
https://doi.org/10.1016/j.euo.2020.09.001
Autor:
Andrew M. Hiar, Michael Bates, Richard Harris, Kevin Cline, Iris M. Simon, Julia A. Bridge, Yair Lotan, F Johannes P van Valenberg, Alon Z. Weizer, Russell B. Egerdie, Brian Rhees, Eric W. Klein, Safedin Beqaj, Donna Mayne, Bernard Goldfarb, Andrew F. Trainer, J. Alfred Witjes, Ellen Wallace, Fred Wolk, Arnulf Stenzl, Timothy J. Bradford, Joseph Zadra, Suling Zhao, Michael B. Williams, Godfrey K. Jansz, Karl R. Westenfelder, Richard D. David, Timothy A. Richardson, Wade J. Sexton, Russell Higuchi, Scott Campbell, Barry Shepard, John Danella, Sijian Ge, Scott Montgomery
Publikováno v:
European Urology, 75, 853-860
European Urology, 75, 5, pp. 853-860
European Urology, 75, 5, pp. 853-860
Background A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d3201942008d977ce653d5a31275c79
https://doi.org/10.1016/j.eururo.2018.11.055
https://doi.org/10.1016/j.eururo.2018.11.055
Autor:
Teuvo L.J. Tammela, Benjamin Z. Leder, Matthew R. Smith, Paul Sieber, Fred Saad, Carsten Goessl, Roger Dansey, R B Egerdie, Jiri Heracek, Chunlei Ke
Publikováno v:
Prostate Cancer and Prostatic Diseases. 15:308-312
Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d337c654906ee9547d7274ee5f4d47d
https://doi.org/10.1038/pcan.2012.18
https://doi.org/10.1038/pcan.2012.18
Autor:
Jack Barkin, E Hirshberg, Kevin V. Carlson, J Corcos, Jane Schulz, L Stothers, Harold P. Drutz, Peter Pommerville, B Egerdie, Sender Herschorn, Jerzy B. Gajewski, Sidney B. Radomski
Publikováno v:
Current Medical Research and Opinion. 27:375-382
Overactive bladder (OAB) is a common condition whose prevalence increases with age. Antimuscarinic agents are the pharmacologic treatment of choice, but adverse events such as dry mouth may lead to early discontinuation. The purpose of this analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6eb4f6b584b68000dd84daa076b8749
https://doi.org/10.1185/03007995.2010.541433
https://doi.org/10.1185/03007995.2010.541433
Autor:
David Sussman, Heinrich Schulte-Baukloh, Russell B Egerdie, Karel Everaert, Kristin Khalaf, Jennifer Gruenenfelder, Manher Joshi, Quanhong Ni
Publikováno v:
INTERNATIONAL JOURNAL OF UROLOGY
Objective To evaluate the impact of onabotulinumtoxinA on individual domains of the quality of life questionnaires in a pooled analysis of two phase 3 trials in overactive bladder patients with urinary incontinence who were inadequately managed by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da80494ebfa10df3bee712eda7e9f8f0
https://pubmed.ncbi.nlm.nih.gov/26391359
https://pubmed.ncbi.nlm.nih.gov/26391359
Autor:
V. Keppenne, Andrew Magyar, Benjamin M. Brucker, Emmanuel Chartier-Kastler, B. Egerdie, A. Kohan, P. Denys, Brenda Jenkins, J. Nicandro
Publikováno v:
Progrès en Urologie. 26:751
Objectifs We evaluated the efficacy/safety of onabotulinumtoxin A 100U versus placebo for treatment of urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO) in non-catheterising multiple sclerosis (MS) patients inadequately managed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::542f97638a8a8703b5dd1e050d0e835a
https://doi.org/10.1016/j.purol.2016.07.170
https://doi.org/10.1016/j.purol.2016.07.170
Autor:
P. Denys, Emmanuel Chartier-Kastler, V. Keppenne, A. Magyar, J.P. Nicando, Benjamin M. Brucker, B. Egerdie, Brenda Jenkins, A. Kohan
Publikováno v:
European Urology Supplements. 15:e647
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::376e4dc306c8e4b4207194d0242c61d0
https://doi.org/10.1016/s1569-9056(16)60649-8
https://doi.org/10.1016/s1569-9056(16)60649-8
Autor:
B. Egerdie, K. Melich, Roger S. Rittmaster, I. M. Nandy, M. S. Lucia, Neil Fleshner, Libby Black
Publikováno v:
European Urology Supplements. 10:51-52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5590167b21c9f4e050eb290343716879
https://doi.org/10.1016/s1569-9056(11)60082-1
https://doi.org/10.1016/s1569-9056(11)60082-1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Urology. 74:S72-S73
1. Abrami,L, et al(1998) The pore-forming toxin proaerolysin is activated by furin. J Biol Chem. 273, 32656-32661. 2. Williams,SA, et al. (2007) A prostate-specific antigenactivated channel-forming toxin as therapy for prostatic disease. J Natl Cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbe4e2de5edcf5750226dc5a3c854e2f
https://doi.org/10.1016/j.urology.2009.07.999
https://doi.org/10.1016/j.urology.2009.07.999